Contact form:

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Realeve Wins Gold in 2023 Merit Awards for Healthcare

November 10, 2023

Realeve Wins Gold in 2023 Merit Awards for Healthcare

Company awarded in Innovations category for Pulsante micro-neurostimulator system

EFFINGHAM, Ill. – November 10, 2023 – Realeve today announced it has won a 2023 Merit Award for Healthcare. The company received Gold status in the Innovation category for its Pulsante micro-neurostimulator system to treat brain-related disorders. The Merit Awards for Healthcare is an independent awards program that recognizes global industries and the markets they serve.

"Realeve’s proven success is delivering hope to millions of people suffering from brain-related disorders across the world," said Dr. Peter Bonutti, founder and president, Realeve. “To be recognized with a 2023 Merit Award for Healthcare is validation of our ongoing efforts and our entire team is very proud to receive this honor.”

The Merit Awards for Healthcare were judged based on submissions that addressed various healthcare needs ranging from services to innovations. The nominated companies underwent a comprehensive review by industry executives, members of the media and consultants.


“Healthcare is a critical part of our lives, whether business or personal,” said Marie Zander, executive director, Merit Awards. “We were thrilled to receive the submissions that spoke to the services, products, innovations and technologies that are shaping the healthcare marketplace. Congratulations to all of this year’s winners.” 

Realeve is the first externally powered implantable neuromodulation device for the treatment of central nervous system disorders including stroke and cluster headache. Realeve’s technology has already been clinically proven in more than 700 patients and has also been granted Breakthrough Device designation by the FDA. Realeve’s ultimate goal is to solve one of the critical remaining barriers in brain health which is the ability to bypass the brain's natural barrier to deliver therapeutics.

For more information on Realeve, visit

About Realeve, LLC:

Realeve is a medical device company focused on developing novel treatments for diseases and conditions of the CNS by controlling the SPG via the Pulsante micro-neurostimulator system. Founded in 2019, Realeve builds on over a decade of safe and proven efficacy of the Pulsante system. For more information, visit


Investigational device. Limited by Federal (or United States) law to investigational use.

Media Contact

Donna Loughlin Michaels for Realeve


(408) 393-5575